These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms today.If you are looking to day trade, you might want to check out the following stocks. I usually throw these on my watch list and monitor with resistance & support levels.You can also check previous stocks to buy reports- Right Here.
Pan American Silver (PAAS), U.S. Bancorp (USB), VIVUS (VVUS), Rovi (ROVI), Gap (GPS) and InvenSense (INVN) were upgraded or downgraded by analysts.
Pan American Silver (PAAS) initiated with a Buy at Deutsche Bank.Target $31.
U.S. Bancorp (USB) downgraded to Market Perform from Outperform at BMO Capital.BMO Capital downgraded U.S. Bancorp based on valuation. Price target raised to $34 from $33.
VIVUS (VVUS) upgraded to Buy from Hold at Brean Murray.Brean Murray said the FDA panel meeting clearly demonstrated a health benefit for weight loss, which will put more pressure on the FDA to approve an obesity drug. The firm expects VIVUS's Qnexa to be approved and upgraded shares an established a $30 price target.
Rovi (ROVI) coverage resumed with a Neutral at Goldman.Target $33.
Gap (GPS) upgraded to Buy from Neutral at Janney Capital.Janney upgraded GAP based on improved merchandising, inventory management, and expected margin improvements in 2H 2012. Price target raised to $33 from $29.
InvenSense (INVN) downgraded to Perform from Outperform at Oppenheimer.Oppenheimer downgraded InvenSense ahead of the May 15 lock-up expiration citing valuation and competition. Price target remains $15.
U.S. Bancorp (USB) downgraded to Market Perform from Outperform at BMO Capital.BMO Capital downgraded U.S. Bancorp based on valuation. Price target raised to $34 from $33.
VIVUS (VVUS) upgraded to Buy from Hold at Brean Murray.Brean Murray said the FDA panel meeting clearly demonstrated a health benefit for weight loss, which will put more pressure on the FDA to approve an obesity drug. The firm expects VIVUS's Qnexa to be approved and upgraded shares an established a $30 price target.
Rovi (ROVI) coverage resumed with a Neutral at Goldman.Target $33.
Gap (GPS) upgraded to Buy from Neutral at Janney Capital.Janney upgraded GAP based on improved merchandising, inventory management, and expected margin improvements in 2H 2012. Price target raised to $33 from $29.
InvenSense (INVN) downgraded to Perform from Outperform at Oppenheimer.Oppenheimer downgraded InvenSense ahead of the May 15 lock-up expiration citing valuation and competition. Price target remains $15.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
